Shardul Amarchand Mangaldas & Co. advised Morgan Stanley on Acquisition of Majority Stake in Clearmedi Healthcare
Shardul Amarchand Mangaldas & Co. advised Morgan Stanley on Acquisition of Majority Stake in Clearmedi Healthcare
Shardul Amarchand Mangaldas advised Morgan Stanley on the acquisition of a significant majority stake in Clearmedi Healthcare Private Limited (“Company”) by way of purchase of shareholding of the Company from the existing investors, namely, KOS SPA (“KOS”) and Clearview Healthcare Private Limited. The deal also included issuance and allotment of equity shares of the Company to both Morgan Stanley and Mr. Shashi Kant Baliyan (i.e., the founder of the Company). The deal closed on 28 June 2023.
The proposed transaction marks a complete exit for KOS, an early-stage investor in the Company.
The transaction team was led by Nivedita Tiwari, Partner; Abhinav Kumar, Principal Associate; Kuhuk Jain, Senior Associate; Anupama Singh, Senior Associate.
The due diligence team was led by Nivedita Tiwari, Partner; Devesh Pandey, Partner; Manika Brar, Partner; Nawneet Vibhaw, Partner; Leoni Mahanta, Principal Associate; Suruchi Kumar, Principal Associate; Anupama Singh, Senior Associate; Bulbul Tiwari, Senior Associate; Rudra Pratap Tripathi, Associate; Rohan Bhargava, Associate; Arjav Kulshreshtha, Associate; Prannoy Sebastian, Associate.
ABAC Diligence and Advisory team was led by Alina Arora - Partner, Apurva Zutshi - Principal Associate, Parth Singh - Principal Associate.
Due Diligence Team: Ajit Warrier – Partner, Nimish Malpani – Senior Associate, Suryansh Gupta – Senior Associate, Prakriti Sharma – Senior Associate, Vedashree Ravishankar – Senior Associate, Asmita Vijay Hedge – Associate.
PWC advised Morgan Stanley on the tax related aspect.
Khaitan & Co. advised KOS on the legal aspect.
Phoenix Legal advised the Founder on the legal aspect.
